NEW YORK--(BUSINESS WIRE)--

Levi & Korsinsky, LLP announces that it has commenced an investigation of Trinity Biotech plc (“Trinity” or the “Company”) (NASDAQ:TRIB) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.

On October 4, 2016, Trinity revealed that it was withdrawing its 510(k) premarket notification submission for the Meritas Troponin-I Test and Meritas Point-of-Care Analyzer, following the U.S. Food and Drug Administration’s advice. Trinity also said it would decrease its spending by roughly 85%, to $1.5 million from $9 million each year, and that it would close its Swedish facility, eliminating 40 jobs. Following this news, Trinity stock dropped $6.53 per share, more than 50 percent, to close at $6.46 on October 4, 2016. To obtain additional information about the investigation, go to:

http://zlk.9nl.com/trinity-biotech-trib

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161005006470/en/